References:
  1. Maitra A, Bhattacharyya S, Mukherjee S, Era N. A rare case of oxcarbazepine induced Stevens Johnson Syndrome: toxic epidermal necrosis overlap. International Journal of Basic & Clinical Pharmacology . 2017;6(2):466-468.
  2. Beken B, Can C, Örencik A, Can N, Yazıcıoğlu M. Oxcarbazepine-induced Stevens–Johnson syndrome: a pediatric case report. Oxf Med Case Reports . 2017;2017(6).
  3. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau J-C. Correlations Between Clinical Patterns and Causes of Erythema Multiforme Majus, Stevens-Johnson Syndrome, and Toxic Epidermal Necrolysis: Results of an International Prospective Study.Arch Dermatol . 2002;138(8).
  4. Devi K, George S, Criton S, Suja V, Sridevi P. Carbamazepine - The commonest cause of toxic epidermal necrolysis and Stevens-Johnson syndrome: A study of 7 years. Indian J Dermatol Venereol Leprol . 2005;71(5):325.
  5. Guleria VS, Sharda C, Rana T, Sood AK. Oxcarbazepine induced toxic epidermal necrolysis - a rare case report. Indian Journal of Pharmacology . 2015;47(4):459.
  6. Lin L-C, Lai P-C, Yang S-F, Yang R-C. Oxcarbazepine-induced Stevens-Johnson Syndrome: A Case Report. The Kaohsiung Journal of Medical Sciences . 2009;25(2):82-86.
  7. Trivedi BS, Darji NH, Malhotra SD, Patel PR. Antiepileptic Drugs-induced Stevens–Johnson syndrome: A case Series. J Basic Clin Pharm . 2016;8(1):42-44.
  8. Petrova G, Stoimenova A, Dimitrova M, Kamusheva M, Petrova D, Georgiev O. Assessment of the expectancy, seriousness and severity of adverse drug reactions reported for chronic obstructive pulmonary disease therapy. SAGE Open Med . 2017;5.
  9. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clinical Pharmacology & Therapeutics . 1981;30(2):239-245.
  10. Hartwig SC, Siegel J, Schneider PJ. Preventability and severity assessment in reporting adverse drug reactions. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists . 1992;49(9):2229-2232.
  11. World Health Organization. The use of the WHO-UMC system for standardized case causality assessment. Uppsala: The Uppsala Monitoring Centre; 2005.
  12. Dinulos JGH, Habif TP. Chapter 18: Hypersensitivity Syndromes and Vasculitis. In: Dinulos JGH, ed. Habif’s Clinical Dermatology: A Color Guide to Diagnosis and Therapy . Seventh edition. Philadelphia: Elsevier, 2020:713-747.
  13. Burks AW, Holgate ST, O’Hehir RE, Bacharier LB, Broide DH, Hershey GK, Peebles RS. Chapter 77: Drug Allergy. In:SolenskyR,PhillipsEJ, ed. Middleton’s allergy: Principles and practice . Ninth edition. Amsterdam: Elsevier, 2020:1261-1282.
  14. Chung W-H, Hung S-I, Yang J-Y, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med . 2008;14(12):1343-1350.
  15. Schmidt D, Elger CE. What is the evidence that oxcarbazepine and carbamazepine are distinctly different antiepileptic drugs?Epilepsy Behav . 2004;5(5):627-635.